Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - Multiple bladder cancer recurrences are more likely to occur in patients with high-risk disease. Association between recurrences and aggressive treatment in patients who have recurrent high-grade bladder cancer has not be reported. Karim Chamie and colleagues’ objectives were to determine if increase in number of recurrences correlated with higher treatment rates.

auaThe authors used the SEER-Medicare database to identify patients with recurrent high-grade disease diagnosed from 1992-2002 and followed until 2007. They then quantified the incidence of treatments including radical cystectomy, radiotherapy, and systemic chemotherapy after each recurrence.

Of the 4 521 patients identified by the authors, 2 694 of them had more than one recurrence after diagnosis in the first 2 years. Patients with higher number of recurrences (> 4) were less likely to undergo radical cystectomy and more likely to undergo radiotherapy and systemic chemotherapy. In addition, they reported that patients with multiple recurrences had a lower rate of treatment with goals of cure. Ten year cancer specific mortality rates were 6.9%, 9.7%, 13.7%, and 15.7% for those with 1, 2, 3, and > 4 recurrences

The authors concluded that only 25% of patients with high-risk bladder carcinoma and multiple recurrences will undergo intended curative treatment. They also concluded that the treatment course of the patient does not appear to change, regardless of the number of recurrences the patient has. The findings have great clinical implications as mortality rates increase with higher number of recurrences. As the percentage of patients undergoing treatment remains the same with multiple recurrences, patients should get the results of the study in a clear way in order to make better-informed decisions.

Presented by Eric Ballon Landa, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Los Angeles, CA USA

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com

 

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting